Search Within

Kenneth Offit

  1. "Meeting abstract"
Formats
  1. Meeting Abstract (216)
Groups
  1. Clinical Genetics Service (216)
  2. Department of Medicine (216)
  3. GSK Faculty (216)
  4. Population Sciences Research Program (216)
  5. Solid Tumor Oncology Division (216)
  6. Survivorship Research (216)

More Groups

People
  1. Mark Robson (92)
  2. Zsofia Stadler (63)
  3. Vijai Joseph (56)
  4. Diana Mandelker (38)
  5. Yelena Kemel (37)
  6. Michael Walsh (31)

More People

Years
  1. 2025 (1)
  2. 2024 (5)
  3. 2023 (14)
  4. 2022 (7)
  5. 2021 (9)
  6. 2020 (11)

More Years

Publications
  1. Journal of Clinical Oncology (93)
  2. Cancer Research (27)
  3. American Journal of Human Genetics (20)
  4. Blood (15)
  5. Laboratory Investigation (7)
  6. Gynecologic Oncology (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (93)
  2. American Association for Cancer Research (30)
  3. Cell Press (20)
  4. American Society of Hematology (15)
  5. Elsevier Inc. (11)
  6. Springer (11)

More Publishers

Results (216)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
    Meeting Abstract

    Chen, Y. W.; Liu, L.; Cheng, Y.; Araneta, A.; Castano, N.; Gomez, J.; Ajmera, A.; Ye, H.; Runcie, K.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Characterising the contribution of rare protein-coding variants to prostate cancer risk and severity in 36,866 cases
    Meeting Abstract

    Mitchell, J.; Camacho, N.; Shea, P. R.; Stopsack, K.; Joseph, V.; Burren, O.; Penney, K.; Berchuck, J.; Wang, Q. L.; Goldstein, D.; more...
    European Journal of Human Genetics (2024)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
    Meeting Abstract

    McKay, R. R.; Liu, L.; Pu, M.; Araneta, A.; Wang, L.; Castano, N.; Gomez, J.; Ajmera, A.; Ye, H.; Pili, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Leveraging data aggregators to annotate deidentified genomic data derived from commercial laboratory specimens to study COVID-19 severity
    Meeting Abstract

    Dandiker, S.; Latham, A.; Tanpaiboon, P.; Ratajski, A. M.; Bare, L.; Chanock, S.; Fesko, Y. A.; Joseph, V.; Offit, K.
    Value in Health (2024)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
    Meeting Abstract

    McKay, R. R.; Liu, L.; Pu, M.; Araneta, A.; Yuen, K. L.; Gomez, J.; Castano, N.; Ajmera, A.; Ye, H.; Pili, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Germline and somatic MUTYH mutations: Clinicopathologic and mutational analysis in a pan-cancer cohort
    Meeting Abstract

    Desilets, A.; Repetto, M.; Kemel, Y.; Khurram, A.; Mandelker, D.; Bandlamudi, C.; Novak, B.; Velilla, C.; Selenica, P.; Richards, A. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Genetic determinants of clonal hematopoiesis and progression to hematologic malignancies in 479,117 individuals
    Meeting Abstract

    Liu, J.; Tran, D.; Chan, I. C. C.; Wiley, B.; Watson, C.; Batchi-Bouyou, A. L.; Zong, X.; Stopsack, K. H.; Pharoah, P.; Ding, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Germline drivers of gynecologic carcinosarcoma
    Meeting Abstract

    Sia, T.; Birsoy, O.; Kemel, Y.; Maio, A.; Salo-Mullen, E.; Sheehan, M.; Hensley, M.; Rubinstein, M.; Makker, V.; Grisham, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants
    Meeting Abstract

    Shah, P. D.; Brower, J.; Cuff, L.; Richardville, R.; Hamilton, J. G.; Garber, J. E.; Yadav, S.; Couch, F.; Offit, K.; Domchek, S. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings
    Meeting Abstract

    Walsh, M. F.; Fiala, E.; Birsoy, O.; Haque, T.; Stein, E. M.; Shukla, N.; Sulis, M. L.; Goldberg, A. D.; Rana, S.; Khurram, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save